<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2021-434-441</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Клеточный состав воспалительных инфильтратов малой слюнной железы как дополнительный диагностический критерий первичного синдрома Шегрена</article-title><trans-title-group xml:lang="en"><trans-title>Cellular composition of the minor salivary gland inflammatory infiltrates as an additional diagnostic criterion for primary Sjogren’s syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8598-0391</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кувардин</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuvardin</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Российская Федерация, Санкт-Петербург, ул. Аккуратова, 2</p></bio><bio xml:lang="en"><p>197341, Russian Federation, Saint Petersburg, Akkuratova str., 2</p></bio><email xlink:type="simple">evgenkuv23@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9619-1048</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Григорьева</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Grigor’yeva</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Российская Федерация, Санкт-Петербург, ул. Аккуратова, 2</p></bio><bio xml:lang="en"><p>197341, Russian Federation, Saint Petersburg, Akkuratova str., 2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5206-3367</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бехтерева</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bekhtereva</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198015, Российская Федерация, Санкт-Петербург, ул. Кирочная, 41</p></bio><bio xml:lang="en"><p>191015, Russian Federation, Saint-Petersburg, Kirochnaya str., 41</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2427-4148</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маслянский</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Maslyansky</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Российская Федерация, Санкт-Петербург, ул. Аккуратова, 2</p></bio><bio xml:lang="en"><p>197341, Russian Federation, Saint Petersburg, Akkuratova str., 2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9872-0326</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Криволапов</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivolapov</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198015, Российская Федерация, Санкт-Петербург, ул. Кирочная, 41</p></bio><bio xml:lang="en"><p>191015, Russian Federation, Saint-Petersburg, Kirochnaya str., 41</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1677-9237</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белякова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyakova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>198015, Российская Федерация, Санкт-Петербург, ул. Кирочная, 41</p></bio><bio xml:lang="en"><p>191015, Russian Federation, Saint-Petersburg, Kirochnaya str., 41</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Almazov National Medical Research Centre<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">North-Western State Medical University named after I.I. Mechnikov<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>05</day><month>09</month><year>2021</year></pub-date><volume>59</volume><issue>4</issue><elocation-id>434–441</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Кувардин Е.С., Григорьева И.Н., Бехтерева И.А., Маслянский А.Л., Криволапов Ю.А., Белякова Е.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кувардин Е.С., Григорьева И.Н., Бехтерева И.А., Маслянский А.Л., Криволапов Ю.А., Белякова Е.А.</copyright-holder><copyright-holder xml:lang="en">Kuvardin E.S., Grigor’yeva I.N., Bekhtereva I.A., Maslyansky A.L., Krivolapov Y.A., Belyakova E.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3061">https://rsp.mediar-press.net/rsp/article/view/3061</self-uri><abstract><p>Болезнь Шегрена, или первичный синдром Шегрена (ПСШ), – одна из самых частых нозологических форм в группе диффузных заболеваний соединительной ткани. Важнейшим методом диагностики ПСШ является гистологическое исследование малой слюнной железы (МСЖ). Имеющиеся в настоящее время гистологические критерии ПСШ не обладают абсолютной чувствительностью и специфичностью, что делает поиск дополнительных морфологических признаков актуальным.</p><p>Цели исследования – изучение качественного и количественного составов клеточных популяций воспали- тельных инфильтратов малой слюнной железы при первичном синдроме Шегрена с разработкой дополни- тельных диагностических критериев заболевания.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 55 пациентов с ПСШ, соответствующих критериям ACR/ EULAR (2016), не получавших ранее генно-инженерные биологические препараты. В группу контроля вошли 18 здоровых добровольцев. Всем исследуемым выполнялась биопсия МСЖ для проведения гистологического и иммуногистохимического исследований с количественной оценкой CD3+, CD4+, CD8+, CD20+, CD21+, CD68+, CD138+-клеток. Статистический анализ результатов проведен с использованием прикладной программы Statistica 10.0 для Windows (StatSoft Inc., США). Для сравнения количественных признаков использовался U-критерий Манна – Уитни. Для определения диагностического порога (ДП) для удельного количества клеток проводился ROC-анализ, строилась кривая операционной характеристики, рассчитывались площадь под кривой (ППК), показатели диагностической специфичности (ДС), диагностической чувствительности (ДЧ), диагностической точности (ДТ), отношение правдоподобия положительного (ОППР) и отрицательного (ОПОР) результатов теста. Построение классификационных моделей, включающих удельное количество разных типов клеток, осуществлялось при помощи линейного дискриминантного анализа.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Количество CD3+, CD4+, CD8+, CD20+, CD138+ клеток в 4 мм2 (площадь среза) было значимо выше в группе ПСШ. Наибольшая ППК наблюдалась для количественной оценки CD3+- клеток – 0,88 [95%-й доверительный интервал (ДИ): 0,80–0,96] и CD8+-клеток – 0,87 [95% ДИ: 0,79–0,95], что при заданных ДП соответствовало ДЧ 70,9% [95% ДИ: 57,86–81,23] и 65,45% [95% ДИ: 52,25–76,64]; ДС – 94,4% [95% ДИ: 74,24–99,72] и 100% [95% ДИ: 82,41–100] соответственно. CD21+ фолликулярные дендритные клетки выявлялись только в группе ПСШ. ППК при количественной оценке этих клеток составляла 0,65 [95% ДИ: 0,52–0,78], ДЧ – 29,1% [95% ДИ: 18,77–42,14], ДС – 100% [95% ДИ: 82,41–100]. Методом дискриминантного анализа были построены классификационные модели, включающие различные комбинации исследуемых клеточных популяций. Наибольшая ППК среди всех возможных сочетаний наблюдалась для десятичных логарифмов удельного количества CD3+ и CD68+-клеток – 0,92 [95% ДИ: 0,85–0,98], что при заданном ДП соответствовало ДЧ 81,82% [95% ДИ: 69,67–89,81] и ДС – 94,4% [95% ДИ:74,24–99,72].</p></sec></abstract><trans-abstract xml:lang="en"><p>Primary Sjogren’s syndrome (pSS) is one of the most frequent among the connective tissue diseases. Histological examination of the minor salivary gland (MSG) is important diagnostic method. The currently established histological criteria for pSS do not have absolute sensitivity and specificity, which makes the search for additional morphological hallmark relevant.</p><p>Aim – to study of the qualitative and quantitative composition of cellular populations inflammatory infiltrates in MSG pSS patient with the assessment of additional diagnostic criteria for disease based on the data obtained.</p><sec><title>Subjects and methods</title><p>Subjects and methods. The study included 55 patients with a diagnosis of pSS according to the criteria of ACR/ EULAR 2016. The control group consisted of 18 healthy volunteers. A MSG biopsy was performed all subjects for histological and immunohistochemical studies with a quantitative assessment of CD3+, CD4+, CD8+, CD20+, CD21+, CD68+, CD138+ cells. Statistical data analysis was performed using the Statistica 10.0 for Windows (StatSoft Inc., USA). For comparison of quantitative traits, the Mann – Whitney U-test was used. To determine the diagnostic threshold of the number of a ROC analysis was performed. An operating characteristic curve was plotted. The area under the curve (AUC), diagnostic specificity, diagnostic sensitivity, diagnostic accuracy, likelihood ratio of the positive and negative results of the test were calculated. The construction of classification models, including the number of different cell types, was carried out using linear discriminant analysis.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The number of CD3+, CD4+, CD8+, CD20+, CD138+ cells in 4 mm2 (area of section) was significantly higher in the pSS group. The largest AUC were observed for the quantitative evaluation of CD3+ cells – 0.88 [95% confidence interval (CI): 0.80–0.96] and CD8+ cells – 0.87 [95% CI: 0.79–0.95], which at the specified diagnostic thresholds corresponded to the sensitivity of 70.9% [95% CI: 57.86–81.23] and 65.45% [95% CI: 52.25–76.64], specificity of 94.4% [95% CI: 74.24–99.72] and 100% [95% CI: 82.41–100], respectively. The CD21+ follicular dendritic cells were detected only in MSG of pSS group. AUC for quantitative assessment of these cells was 0.65 [95% CI: 0.52–0.78], sensitivity 29.1% [95% CI: 18.77–42.14] and specificity 100% [95% CI: 82.41–100]. Using the method of discriminant analysis, we designed classification models that included various combinations of the studied markers. The highest AUC among all possible combinations was observed for the decimal logarithms of the number of CD3+ and CD68+ cells – 0.92 [95% CI: 0.85–0.98], which for a given diagnostic threshold corresponded sensitivity – 81.82% [95% CI: 69.67–89.81], specificity – 94.4% [95% CI: 74.24–99.72].</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>первичный синдром Шегрена</kwd><kwd>биопсия</kwd><kwd>иммуногистохимическое исследование</kwd><kwd>малая слюнная железа</kwd><kwd>Т-клетки</kwd><kwd>В-клетки</kwd><kwd>макрофаги</kwd><kwd>фолликулярные дендритные клетки</kwd><kwd>плазматические клетки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary Sjogren’s syndrome</kwd><kwd>biopsy</kwd><kwd>immunohistochemistry</kwd><kwd>small salivary gland</kwd><kwd>T cells</kwd><kwd>B cells</kwd><kwd>macrophages</kwd><kwd>follicular dendritic cells</kwd><kwd>plasmacytes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017:464.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL (ed.). Rheumatology. Russian clinical guidelines. Moscow:GEOTAR-Media;2017:464 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74:1983-1989. doi: 10.1136/annrheumdis-2014-205375</mixed-citation><mixed-citation xml:lang="en">Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74:1983-1989. doi: 10.1136/annrheumdis-2014-205375</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35-45. doi: 10.1002/art.39859</mixed-citation><mixed-citation xml:lang="en">Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35-45. doi: 10.1002/art.39859</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: A systematic review. Autoimmun Rev. 2013;12:416-420. doi: 10.1016/j.autrev.2012.08.001</mixed-citation><mixed-citation xml:lang="en">Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: A systematic review. Autoimmun Rev. 2013;12:416-420. doi: 10.1016/j.autrev.2012.08.001</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bodeutsch C, de Wilde PC, Kater L, van Houwelingen JC, van den Hoogen FH, Kruize AA, et al. Quantitative immunohistologic criteria are superior to the lymphocytic focus score criterion for the diagnosis of Sjögren’s syndrome. Arthritis Rheum. 1992;35:1075-1087. doi: 10.1002/art.1780350913</mixed-citation><mixed-citation xml:lang="en">Bodeutsch C, de Wilde PC, Kater L, van Houwelingen JC, van den Hoogen FH, Kruize AA, et al. Quantitative immunohistologic criteria are superior to the lymphocytic focus score criterion for the diagnosis of Sjögren’s syndrome. Arthritis Rheum. 1992;35:1075-1087. doi: 10.1002/art.1780350913</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">van Woerkom JM, Kruize AA, Barendregt PJ, Kater L, Hené R, Bootsma H, et al. Clinical significance of quantitative immunohistology in labial salivary glands for diagnosing Sjogren’s syndrome. Rheumatology (Oxford). 2006;45:470-477. doi: 10.1093/rheumatology/kei191</mixed-citation><mixed-citation xml:lang="en">van Woerkom JM, Kruize AA, Barendregt PJ, Kater L, Hené R, Bootsma H, et al. Clinical significance of quantitative immunohistology in labial salivary glands for diagnosing Sjogren’s syndrome. Rheumatology (Oxford). 2006;45:470-477. doi: 10.1093/rheumatology/kei191</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren’s syndrome. Ann Rheum Dis. 2017;76:1161-1168. doi: 10.1136/annrheumdis-2016-210448</mixed-citation><mixed-citation xml:lang="en">Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren’s syndrome. Ann Rheum Dis. 2017;76:1161-1168. doi: 10.1136/annrheumdis-2016-210448</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Navazesh M, Kumar SKS. Measuring salivary flow. Dent Assist J. 2008;139:35S-40S. doi: 10.14219/jada.archive.2008.0353</mixed-citation><mixed-citation xml:lang="en">Navazesh M, Kumar SKS. Measuring salivary flow. Dent Assist J. 2008;139:35S-40S. doi: 10.14219/jada.archive.2008.0353</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome. Clin Rheumatol. 2007;26:1099-1103. doi: 10.1007/s10067-006-0457-1</mixed-citation><mixed-citation xml:lang="en">Teppo H, Revonta M. A follow-up study of minimally invasive lip biopsy in the diagnosis of Sjögren’s syndrome. Clin Rheumatol. 2007;26:1099-1103. doi: 10.1007/s10067-006-0457-1</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14:1019-1022. doi: 10.1016/j.autrev.2015.07.002</mixed-citation><mixed-citation xml:lang="en">Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14:1019-1022. doi: 10.1016/j.autrev.2015.07.002</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–407. doi: 10.1016/j.jaut.2009.10.004</mixed-citation><mixed-citation xml:lang="en">Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–407. doi: 10.1016/j.jaut.2009.10.004</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jonsson MV, Skarstein K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren’s syndrome. J Oral Pathol Med. 2008;37:515-521. doi: 10.1111/j.1600-0714.2008.00674.x</mixed-citation><mixed-citation xml:lang="en">Jonsson MV, Skarstein K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren’s syndrome. J Oral Pathol Med. 2008;37:515-521. doi: 10.1111/j.1600-0714.2008.00674.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Braun M, Melchers I, Peter HH, Illges H. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int Immunol. 1998;10(8):1197-1202.</mixed-citation><mixed-citation xml:lang="en">Braun M, Melchers I, Peter HH, Illges H. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int Immunol. 1998;10(8):1197-1202.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2006;54:2280-2288. doi: 10.1002/art.21936</mixed-citation><mixed-citation xml:lang="en">Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2006;54:2280-2288. doi: 10.1002/art.21936</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, et al. Ectopic germinal centers are rare in Sjogren’s syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182:3540-3547. doi: 10.4049/jimmunol.0803588</mixed-citation><mixed-citation xml:lang="en">Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, et al. Ectopic germinal centers are rare in Sjogren’s syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182:3540-3547. doi: 10.4049/jimmunol.0803588</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ushio A, Arakaki R, Yamada A, Saito M, Tsunematsu T, Kudo Y, et al. Crucial roles of macrophages in the pathogenesis of autoimmune disease. World J Immunol. 2017;7(1):1-8. doi: 10.5411/wji.v7.i1.1</mixed-citation><mixed-citation xml:lang="en">Ushio A, Arakaki R, Yamada A, Saito M, Tsunematsu T, Kudo Y, et al. Crucial roles of macrophages in the pathogenesis of autoimmune disease. World J Immunol. 2017;7(1):1-8. doi: 10.5411/wji.v7.i1.1</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ushio A, Arakaki R, Otsuka K, Yamada A, Tsunematsu T, Kudo Y, et al. CCL22-producing resident macrophages enhance T cell response in Sjögren’s syndrome. Front Immunol. 2018;9:2594. doi: 10.3389/fimmu.2018.02594</mixed-citation><mixed-citation xml:lang="en">Ushio A, Arakaki R, Otsuka K, Yamada A, Tsunematsu T, Kudo Y, et al. CCL22-producing resident macrophages enhance T cell response in Sjögren’s syndrome. Front Immunol. 2018;9:2594. doi: 10.3389/fimmu.2018.02594</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
